Northwest Biotherapeutics Stock Forecast for 2023 - 2025 - 2030
Updated on 04/19/2024
Northwest Biotherapeutics Fair Value Forecast for 2023 - 2025 - 2030
Northwest Biotherapeutics's Price has grown In the last year, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $0.00 – an increase of 100.00%. For the next six years, experts predict that Northwest Biotherapeutics's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$233.15 | Buy/Sell | $284.47 | 20.09% |
| FATE Stock Forecast | Fate Therapeutics | Outperform |
7
|
$5.04 | Buy/Sell | $6.23 | 38.89% |
| CAPR Stock Forecast | Capricor Therapeutics | Buy |
0
|
$5.05 | Buy/Sell | $13.50 | 256.44% |
| FBIO Stock Forecast | Fortress Biotech | Buy |
11
|
$1.81 | Buy/Sell | $67.50 | 314.36% |
| PIRS Stock Forecast | Pieris Pharmaceuticals | - |
9
|
$0.16 | Buy/Sell | $7.00 | -100.00% |
Northwest Biotherapeutics Revenue Forecast for 2023 - 2025 - 2030
Northwest Biotherapeutics's Revenue has grown In the last three years, rising from $1.29M to $1.93M – a growth of 49.61%. In the following year, the 0 analysts surveyed believe that Northwest Biotherapeutics's Revenue will decrease by 8.37%, reaching $1.77M. According to professionals, by 2030, Northwest Biotherapeutics's Revenue will have decreased by 15.61%, falling down to $1.63M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ONTX Stock Forecast | Onconova Therapeutics | Buy |
6
|
$0.68 | Buy/Sell | $11.50 | 929.41% |
| PSTV Stock Forecast | Plus Therapeutics | Outperform |
11
|
$1.69 | Buy/Sell | $11.00 | 373.37% |
| CYCC Stock Forecast | Cyclacel Pharmaceuticals | Outperform |
5
|
$1.85 | Buy/Sell | $240.00 | 8710.81% |
.jpg)
Northwest Biotherapeutics EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Northwest Biotherapeutics's EBITDA has decreased by 37.61%, from $-86.52M to $-53.98M. In the next year, analysts predict that EBITDA will jump to $-65.99M – up 22.26% from the current level. Looking ahead to seven years, experts forecast that EBITDA will grow by 17.17%.
Northwest Biotherapeutics EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Northwest Biotherapeutics's EBIT has fallen from $-86.61M to $-55.51M – a 35.91% decrease. Analysts predict that Northwest Biotherapeutics's EBIT will increase in the upcoming year, reaching $-67.32M. This would represent an increase of 21.27%. Over the next seven years, experts predict that Northwest Biotherapeutics's EBIT will grow at a rate of 15.86%.
Northwest Biotherapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030
Northwest Biotherapeutics's EPS has grown In the last year, rising from $-0.85 to $0.00 – a growth of 100.00%. In the next year, analysts believe that EPS will reach $0.00 – an increase of 100.00%. For the next six years, experts predict that Northwest Biotherapeutics's EPS will grow at a rate of 100.00%.
Site Navigation
.jpg)